SuperworthCartesian Therapeutics RNAC
- Market cap
- $187M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −42.0%
Cartesian Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.6M−68% | $8.3M−51% | $5.8M−2% | $33.4M+537% | $387K−94% | n/a | $1.1M−81% | $298K−99% | $452K+17% | n/a | $78K−93% | $0 | |
| R&D | $13M−21% | $21.9M+15% | $9.7M−48% | $12.7M−29% | $11.4M−12% | n/a | $14.7M+51% | $14.9M+17% | $13.8M+21% | n/a | $19.5M+33% | $20.4M+37% |
| SG&A | $6.6M+15% | $22M+249% | $9.4M+66% | $7M+15% | $6.6M−1% | n/a | $8.3M−12% | $7.2M+3% | $7.7M+18% | n/a | $7.1M−14% | $8.7M+21% |
| −$13.1M+717% | −$36.3M+328% | −$13.3M−27% | $13.8M | −$17.6M+35% | n/a | −$21.9M+64% | −$21.8M | −$21.1M+20% | n/a | −$26.5M+21% | −$29.2M+34% | |
| Interest expense | $1.3M+59% | $0 | $0 | $0 | $0 | $0 | n/a | $0 | n/a | n/a | n/a | $852K |
| Pre-tax income | −$9M+10% | −$196.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$9M+14% | −$177.7M | −$56.8M+162% | $13.8M | −$24.2M+169% | −$10.3M−94% | −$17.7M−69% | $15.9M+15% | −$35.9M+49% | −$92.6M+803% | −$39.2M+121% | $15.8M−1% |
| −$1.74+16% | −$40.66 | −$10.50+148% | $0.54 | −$1.13−35% | −$0.40−99% | −$0.68−94% | $0.50−7% | −$1.38+22% | −$3.56+790% | −$1.46+115% | $0.46−8% | |
| 5.2M+1% | 5.3M+4% | 5.4M+6% | 17.8M+248% | 21.5M+316% | 25.4M+379% | 25.9M+378% | 26.4M+49% | 26M+21% | 26M+3% | 26.9M+4% | 29.9M+13% |
Revenue: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
R&D: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
SG&A: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Operating income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Net income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21 and Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Cartesian Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RNACCartesian Therapeutics | $187M | n/m | 20.6× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $523.1M | 11.3× | 13.6× | 1.4× | +7% | 11.6% |
More on Cartesian Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .